{"id":47555,"date":"2025-11-05T12:00:00","date_gmt":"2025-11-05T11:00:00","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/11\/05\/consecutive-non-aspergillus-fungal-invasive-infections-in-chronic-granulomatous-disease-data-from-the-french-national-reference-center-for-primary-immunodeficiencies-and-literature-review\/"},"modified":"2025-11-05T12:00:00","modified_gmt":"2025-11-05T11:00:00","slug":"consecutive-non-aspergillus-fungal-invasive-infections-in-chronic-granulomatous-disease-data-from-the-french-national-reference-center-for-primary-immunodeficiencies-and-literature-review","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/11\/05\/consecutive-non-aspergillus-fungal-invasive-infections-in-chronic-granulomatous-disease-data-from-the-french-national-reference-center-for-primary-immunodeficiencies-and-literature-review\/","title":{"rendered":"Consecutive non-Aspergillus Fungal Invasive Infections in Chronic Granulomatous Disease: Data from the French National Reference Center for Primary ImmunoDeficiencies and literature review"},"content":{"rendered":"
\n

J Clin Immunol<\/b>. 2025 Nov 6;45(1):152. doi: 10.1007\/s10875-025-01903-0.<\/p>\n

ABSTRACT<\/b><\/p>\n

BACKGROUND: Non-Aspergillus invasive fungal infections (NAFI) are increasingly reported in patients with Chronic Granulomatous Disease (CGD), but precise clinical descriptions remain scarce.<\/p>\n

OBJECTIVE AND METHODS: We conducted a retrospective analysis of NAFI cases among CGD patients in the French National Registry of Primary Immunodeficiencies (CEREDIH) and in a comprehensive literature review.<\/p>\n

RESULTS: We identified 16 proven NAFI (9 molds, 6 yeasts and 1 Pneumocystis) among 263 CGD patients from CEREDIH and included an additional 106 probable\/proven NAFI from a literature review (75 molds, 29 yeasts, 1 Pneumocystis, 1 dimorphic). Mold NAFI occurred at a median age of 17 years [IQR 9-23], and were mostly located to the lungs (79%, 65\/82). Mold NAFI were breakthrough in 59% of patients (35\/59), and 24% were receiving immunosuppressive treatments (13\/54, mostly high-dose corticosteroids, n = 11). Lung surgical biopsies yielded the highest diagnostic rate (39\/39) compared to less invasive methods (BAL 8\/18 and transthoracic punctures 8\/12). Nine patients with mold NAFI, including 3 refractory cases, were cured after Hematopoietic Stem Cell Transplantation (HSCT). Overall mortality for mold NAFI was 25% (20\/81). Yeast infections occurred at a median age of 5 years [IQR 0-13], and 36% were receiving immunosuppressive treatments (5\/14, mostly anti-TNF agents, n = 4). Infections were frequently located to lymph nodes or lungs, and 64% (21\/33) were disseminated. Two yeast NAFI were cured after HSCT. Mortality was 26% (7\/27).<\/p>\n

CONCLUSION: NAFI in CGD patients are frequently severe, often occur despite prophylaxis and under additional immunosuppression, commonly require invasive procedures for diagnosis, and may be effectively managed with HSCT.<\/p>\n

PMID:41193884<\/a> | DOI:10.1007\/s10875-025-01903-0<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

J Clin Immunol. 2025 Nov 6;45(1):152. doi: 10.1007\/s10875-025-01903-0. ABSTRACT BACKGROUND: Non-Aspergillus invasive fungal infections (NAFI) are increasingly reported in patients with Chronic Granulomatous Disease (CGD), but precise clinical descriptions remain scarce. OBJECTIVE AND METHODS: We conducted a retrospective analysis of NAFI cases among CGD patients in the French National Registry of Primary Immunodeficiencies (CEREDIH) and … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69,42],"tags":[],"class_list":["post-47555","post","type-post","status-publish","format-standard","hentry","category-journal-of-clinical-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/47555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=47555"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/47555\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=47555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=47555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=47555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}